Sponsored
South Korea approved its first domestically developed COVID-19 vaccine, manufactured by SK bioscience Co Ltd (302440.KS), for general public use following positive clinical data, authorities said on Wednesday.
The SKYCovione vaccine was authorised for a two-dose regimen on people aged 18 or older, with shots given four weeks apart, according to the Ministry of Food and Drug Safety.
In a phase III clinical trial of 4,037 adults, SKYCovione induced neutralizing antibody responses against the SARS-CoV-2 parental strain, SK bioscience said in a statement.
Advertisement
